<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">790</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2025-12-2-112-121</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Potential antitumor activity of a new plant-derived alkaloid isolated from <italic>Petasites hybridus</italic> (L.), <italic>in silico</italic> and <italic>in vitro</italic></article-title><trans-title-group xml:lang="ru"><trans-title>Потенциальная противоопухолевая активность нового алкалоида растительного происхождения, выделенного из <italic>Petasites hybridus</italic> (L.), <italic>in silico</italic> и <italic>in vitro</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1410-122X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zlatnik</surname><given-names>E. Yu.</given-names></name><name xml:lang="ru"><surname>Златник</surname><given-names>Е. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Elena Yurievna Zlatnik</p><p>63 14<sup>th</sup> Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>Елена Юрьевна Златник</p><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><email>elena-zlatnik@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4558-5896</contrib-id><name-alternatives><name xml:lang="en"><surname>Filippova</surname><given-names>S. Yu.</given-names></name><name xml:lang="ru"><surname>Филиппова</surname><given-names>С. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th</sup> Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4572-1579</contrib-id><name-alternatives><name xml:lang="en"><surname>Enin</surname><given-names>Yu. S.</given-names></name><name xml:lang="ru"><surname>Енин</surname><given-names>Я. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th</sup> Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4555-8556</contrib-id><name-alternatives><name xml:lang="en"><surname>Chembarova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Чембарова</surname><given-names>Т. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14<sup>th</sup> Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-1682-1344</contrib-id><name-alternatives><name xml:lang="en"><surname>Amirdzhanov</surname><given-names>F. F.</given-names></name><name xml:lang="ru"><surname>Амирджанов</surname><given-names>Ф. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>105/42 Bolshaya Sadovaya St., Rostov-on-Don 344006</p></bio><bio xml:lang="ru"><p>344006 Ростов-на-Дону, ул. Большая Садовая, 105/42</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7704-033X</contrib-id><name-alternatives><name xml:lang="en"><surname>Burov</surname><given-names>O. N.</given-names></name><name xml:lang="ru"><surname>Буров</surname><given-names>О. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>105/42 Bolshaya Sadovaya St., Rostov-on-Don 344006</p></bio><bio xml:lang="ru"><p>344006 Ростов-на-Дону, ул. Большая Садовая, 105/42</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5864-8991</contrib-id><name-alternatives><name xml:lang="en"><surname>Zagrebaev</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Загребаев</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>105/42 Bolshaya Sadovaya St., Rostov-on-Don 344006</p></bio><bio xml:lang="ru"><p>344006 Ростов-на-Дону, ул. Большая Садовая, 105/42</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-6944-9690</contrib-id><name-alternatives><name xml:lang="en"><surname>Onasenko</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Онасенко</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>105/42 Bolshaya Sadovaya St., Rostov-on-Don 344006</p></bio><bio xml:lang="ru"><p>344006 Ростов-на-Дону, ул. Большая Садовая, 105/42</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-5692-2576</contrib-id><name-alternatives><name xml:lang="en"><surname>Dzigunova</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Дзигунова</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>105/42 Bolshaya Sadovaya St., Rostov-on-Don 344006</p></bio><bio xml:lang="ru"><p>344006 Ростов-на-Дону, ул. Большая Садовая, 105/42</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Southern Federal University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Южный федеральный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>112</fpage><lpage>121</lpage><history><date date-type="received" iso-8601-date="2025-06-28"><day>28</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-28"><day>28</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Zlatnik E.Y., Filippova S.Y., Enin Y.S., Chembarova T.V., Amirdzhanov F.F., Burov O.N., Zagrebaev A.D., Onasenko K.A., Dzigunova Y.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Златник Е.Ю., Филиппова С.Ю., Енин Я.С., Чембарова Т.В., Амирджанов Ф.Ф., Буров О.Н., Загребаев А.Д., Онасенко К.А., Дзигунова Ю.В.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Zlatnik E.Y., Filippova S.Y., Enin Y.S., Chembarova T.V., Amirdzhanov F.F., Burov O.N., Zagrebaev A.D., Onasenko K.A., Dzigunova Y.V.</copyright-holder><copyright-holder xml:lang="ru">Златник Е.Ю., Филиппова С.Ю., Енин Я.С., Чембарова Т.В., Амирджанов Ф.Ф., Буров О.Н., Загребаев А.Д., Онасенко К.А., Дзигунова Ю.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/790">https://umo.abvpress.ru/jour/article/view/790</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Some cytostatic drugs are based on the compounds of plant origin. Development of the new plant metabolites-derived antitumor drugs is an actual and perspective trend in oncology. Recently we isolated a compound from the rhizome of <italic>Petasites hybridus</italic> (L.) and identified it as a corynan-like indole alkaloid P1.</p><p><bold>Aim. </bold>To identify of the possibility of the <italic>Petasites hybridus</italic> (L.)-derived alkaloid to bind with molecular targets mediating carcinogenesis and tumor growth and the assessment of its effect on tumor and normal cell cultures.</p><p><bold>Materials and methods.</bold> The research was performed <italic>in silico</italic> by molecular docking and <italic>in vitro</italic> by cultural methods. Molecular docking of alkaloid Р1 with receptors of epidermal growth factor (EGFR), platelet growth factor (PDGFR), MET, MRP2 and NOX4 was carried out using software AutoDock Vina 4.0. The docking area grid was built in AutoDockTools 1.5.7. Cultural experiments were performed on tumor cell line highly expressing EGFR (Н1299) and normal lung fibroblasts. Cells were cultured with various concentrations of the alkaloid, their viability was assessed in ХТТ-test and by direct count of alive and dead cells.</p><p><bold>Results. </bold>Maximal binding energy of alkaloid Р1 with molecular targets was noted for МеТ (–8,6 kcal/M), minimal – for NOX4 (–5,9 kcal/M). Binding energy of alkaloid Р1 with EGFR was –6,4; with PDGFR –7,2; with MRP2 –6,3 kcal/M. Binding of alkaloid P1 occurred with the amino acid residues of the active centers of the majority of the studied receptors. Alkaloid showed the ability to inhibit the growth of H1299 cell line (lung adenocarcinoma) in the wide range of concentrations more actively than of normal fibroblasts: half-maximal inhibitory concentration for P1 was 127,24 and 256,29 μM/l respectively. Maximal difference of the dead cells amount between H1299 line and fibroblasts was observed in alkaloid concentrations 21,7–87 μM/l, but, in spite of some signs of mitotic failure (multinucleate and giantnucleate H1299 cells) mitotic index did not change.</p><p><bold>Conclusion.</bold> Alkaloid isolated from the rhizome of <italic>Petasites hybridus</italic> (L.) is able to bind with the targets mediating tumor growth and impairs lung adenocarcinoma Н1299 cells. Further research is necessary for detailed study of its` antitumor effect in <italic>in vitro</italic> and <italic>in vivo </italic>models.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> В основе некоторых цитостатиков лежат продукты растительного происхождения. Разработка новых противоопухолевых средств на основе метаболитов растений является перспективным и актуальным направлением в онкологии. Ранее путем экстракции из корневищ белокопытника гибридного<italic> </italic>(<italic>Petasites hybridus</italic> (L.)) мы получили соединение, которое расшифровано и идентифицировано как индольный алкалоид P1, близкий по строению к коринану.</p><p><bold>Цель исследования </bold>– определение возможности связывания алкалоида, выделенного из <italic>Petasites hybridus</italic><bold> </bold>(L.), с молекулярными мишенями, обусловливающими канцерогенез и опухолевый рост, оценка его действия на состояние культур опухолевых и нормальных клеток.</p><p><bold>Материалы и методы.</bold> исследование проведено <italic>in silico</italic> методом молекулярного докинга и <italic>in vitro</italic> культуральными методами. Молекулярный докинг алкалоида Р1 с рецепторами эпидермального фактора роста (EGFR), тромбоцитарного фактора роста (PDGFR), MET, MRP2 и NOX4 выполнен с использованием программного обеспечения AutoDock Vina 4.0. Сетка области докинга построена в программе AutoDockTools 1.5.7. культуральные исследования проводили на культуре опухолевых высокоэкспрессирующих EGFR (Н1299) и неопухолевых (нормальные фибробласты легкого) клеток человека. клетки культивировали с различными концентрациями алкалоида, их жизнеспособность оценивали с помощью ХТТ-теста и метода прямого подсчета живых и погибших клеток.</p><p><bold>Результаты.</bold> Максимальный показатель энергии связывания Р1 с молекулярными мишенями получен для МеТ (–8,6 ккал/моль), минимальный – для NOX4 (–5,9 ккал/моль). Энергия связывания Р1 с EGFR составила –6,4; с PDGFR –7,2; с MRP2 –6,3 ккал/моль. Связывание Р1 происходило с аминокислотными остатками активных центров большинства исследованных рецепторов.</p><p>Алкалоид Р1 способен подавлять рост культуры аденокарциномы легкого Н1299 в широком диапазоне концентраций более активно, чем в культуре нормальных фибробластов легкого: концентрация полумаксимального ингибирования Р1 составила 127,24 и 256,29 мкмоль/л соответственно. Максимальные различия количества погибших клеток линии Н1299 по сравнению с фибробластами наблюдались при концентрациях алкалоида 21,7–87 мкмоль/л, однако, несмотря на признаки нарушения митоза в виде наличия крупноядерных и многоядерных клеток культуры Н1299 при действии алкалоида, митотический индекс не менялся.</p><p><bold>Заключение.</bold> Алкалоид, выделенный из белокопытника гибридного, способен связываться с мишенями, опосредующими опухолевый рост, повреждает клетки культуры аденокарциномы легкого Н1299. В связи с этим необходимы дальнейшие исследования его возможного противоопухолевого действия на моделях <italic>in vitro</italic> и <italic>in vivo</italic>.</p></trans-abstract><kwd-group xml:lang="en"><kwd>plant-derived alkaloid</kwd><kwd><italic>Petasites hybridus</italic> (L.)</kwd><kwd>molecular docking</kwd><kwd>receptors</kwd><kwd>tumor cell line</kwd><kwd>tumor growth</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>алкалоид растительного происхождения</kwd><kwd><italic>Petasites hybridus</italic> (L.)</kwd><kwd>молекулярный докинг</kwd><kwd>рецептор</kwd><kwd>культура опухолевых клеток</kwd><kwd>опухолевый рост</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study protocol was approved by the committee on biomedical ethics of the National Medical Research Center of Oncology, Ministry of Health of Russia (protocol No. 7 dated 02.17.2020).</funding-statement><funding-statement xml:lang="ru">Исследование проведено в рамках выполнения государственного задания «Поиск натуральных и синтетических вторичных метаболитов растений, обладающих противоопухолевыми и иммунокорригирующими свойствами на моделях <italic>in vitro</italic> и <italic>in vivo</italic>» (№ 124022100044-2 от 2024 г.).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mushtaq S., Abbasi B.H., Uzairm B., Abbasi R. Natural products as reservoirs of novel therapeutic agents. EXCLI J 2018;4(17):420. DOI: 10.17179/excli2018-1174</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kit O.I., Zhukova G.V., Tolkachev O.N. et al. Antitumor factors of natural origin and some approaches to the development of effective regimens of phytotherapy in oncology (literature review including the findings of authors’ own research). Voprosy onkologii = Problems in Oncology 2022;68(5):27–38. (In Russ.). DOI: 10.37469/0507-3758-2022-68-5-527-538</mixed-citation><mixed-citation xml:lang="ru">Кит О.И., Жукова Г.В., Толкачев О.Н. и др. Противоопухолевые факторы природного происхождения и некоторые подходы к разработке эффективных схем фитотерапии в онкологии (обзор литературы с включением результатов собственных исследований). Вопросы онкологии 2022;68(5):27–38.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Morgillo F., Della Corte C.M., Fasano M., Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 2016;1(3):e000060. DOI: 10.1136/esmoopen-2016-000060</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Du H., Gu J., Peng Q. et al. Berberine suppresses EMT in liver and gastric carcinoma cells through combination with TGFβR regulating TGF-β/Smad pathway. Oxid Med Cell Longev 2021;18(21):2337818. DOI: 10.1155/2021/2337818</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cosme P., Rodríguez A.B., Espino J., Garrido M. Plant phenolics: bioavailability as a key determinant of their potential health promoting applications. Antioxidants (Basel) 2020;9(12):1263. DOI: 10.3390/antiox9121263</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Zlatnik E.Yu., Enin Ya.S., Burov O.N. et al. Molecular and cellular aspects of the impact of secondary metabolites from common barberry and hybrid goat’s rue on the HeLa cell line. Issledovaniya i praktika v meditsine = Research’n Practical Medicine Journal 2023;10(4):31 47. (In Russ.). DOI: 10.17709/2410-1893-2023-10-4-3</mixed-citation><mixed-citation xml:lang="ru">Златник Е.Ю., Енин Я.С., Буров О.Н. и др. Молекулярно-клеточные аспекты воздействия вторичных метаболитов Барбариса обыкновенного и Белокопытника гибридного на клеточную линию HeLa. Исследования и практика в медицине 2023;10(4):31–47. DOI: 10.17709/2410-1893-2023-10-4-3</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Fu W., Liu L., Tong S. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA. Thorac Cancer 2024;15(17):1357. DOI: 10.1111/1759-7714.15321</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Achi I.T., Sarbadhikary P., Blassan P.G., Abrahamse H. Multi-target potential of berberine as an antineoplastic and antimetastatic agent: a special focus on lung cancer treatment. Cells 2022;11(21):3433. DOI: 10.3390/cells11213433</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hassan S.M., Farid A., Panda S.S. et al. Indole compounds in oncology: therapeutic potential and mechanistic insights. Pharmaceuticals 2024;17(7):922. DOI: 10.3390/ph17070922</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Roehm N.W., Rodgers G.H., Hatfield S.M., Glasebrook A.L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991;142(2):257–65. DOI: 10.1016/0022-1759(91)90114-u</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jabbarzadeh K.P., Leong M.P., Ismail P., Ling K.H. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. Pharmacol Rep 2019;71(1):13. DOI: 10.1016/j.pharep.2018.07.005</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Huang B., Wen G., Li R. et al. Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer. Medicine (Baltimore) 2023;102(36):e35070. DOI: 10.1097/MD.0000000000035070</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhang M., Wang C.M., Li J. et al. Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4. Mediators Inflamm 2013;(4):260464. DOI: 10.1155/2013/260464</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sun A., Yang H., Li T. et al. Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies. Front Pharmacol 2024;15(6). DOI: 10.3389/fphar.2024.1368950</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hu M., Yan H., Li H. et al. Use of network pharmacology and molecular docking to explore the mechanism of action of curcuma in the treatment of osteosarcoma. Sci Rep 2023;13:9569. DOI: 10.1038/s41598-023-36687-z</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kang H.N., Kim S.H., Yun M.R. et al. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Lung Cancer 2016;5(95):57–64. DOI: 10.1016/j.lungcan.2016.02.013</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Liu W.J., Wang L., Zhou F.M. et al. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC. Drug Resist Updat 2023;9(70):100987. DOI: 10.1016/j.drup.2023.100987</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Pandey P., Khan F., Upadhyay T.K. et al. New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomed Pharmacother 2023;161:114491. DOI: 10.1016/j.biopha.2023.114491</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chen Z., Vallega K.A., Chen H. et al. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacol Res 2022;1(175):105998. DOI: 10.1016/j.phrs.2021.105998</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chin T.M., Boopathy G.T.K., Man E.P.S. et al. Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors. Theranostics 2020;10(6):2727–43. DOI: 10.7150/thno.38729</mixed-citation></ref></ref-list></back></article>
